Shohei Ishida

Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms

To investigate the predicting factors of therapeutic response to α1‐blockers in patients with lower urinary tract symptoms associated with benign prostate enlargement based on a urodynamic study.

A case of early graft loss due to hyperacute rejection after ABO-incompatible renal transplantation

Abstract:  Graft survival rates of ABO‐incompatible (ABO‐I) living‐related kidney transplantations have greatly improved with the progress of immunosuppressive protocols. However, there are several case reports in which hyperacute rejections (HAR) or delayed hyperacute rejections (DHAR) occurred with immunosuppression, and acute humoral rejection is a risk factor for early graft loss in ABO‐I kidney transplantations. We report a case of early graft loss after ABO‐I kidney transplantation. A 51‐yr‐old male received an ABO‐I kidney transplant from his wife. Graft function deteriorated immediately after surgery and HAR developed. Although plasma exchange and steroid pulse were performed, graft function did not recover. A renal biopsy on postoperative day (POD) 4 indicated compatible findings with HAR. Renal function was deemed irreversible and the renal graft was removed on POD 7. A biopsy performed one h after transplantation revealed a clot in the glomerulus. As this was a case of ABO‐I transplantation without human leukocyte antigen class I and II antibodies in the pre‐ and postoperative flow panel reactive antibody, HAR was most likely caused by the presence of anti‐blood group antibodies. The preoperative anti‐A antibody value of ×64 was rather high in the present case. There is no clear standard for preoperative antibody values and it is difficult to predict prognosis preoperatively with the recent use of strong immunosuppressives. Although the mechanism of onset is unclear in this case, it is believed that the antibody titer should be reduced as much as possible prior to transplantation.

De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy

To investigate storage symptoms following robot‐assisted laparoscopic radical prostatectomy (RARP), focused on de novo overactive bladder (OAB), and to evaluate the factors related to de novo OAB occurrence.

Calcineurin Inhibitor–Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report

BACKGROUND Calcineurin-inhibitor-induced pain syndrome (CIPS) was used as a reference in the literature as reflex sympathetic dystrophy syndrome related to calcineurin inhibitors. Much of the literature describes CIPS that occurred after kidney and bone marrow transplantation. We describe a rare case of CIPS in induction immunosuppression before kidney transplantation, under administration of an anti-rheumatoid drug. METHODS A 53-year-old woman had pre-status of ABO-incompatible living kidney transplantation. The patient had rheumatoid arthritis, but that was well-controlled with salazosulfapyridine as an anti-rheumatoid drug. Fourteen days before transplantation, she received induction immunosuppressive therapy consisting of tacrolimus (TAC) and mycophenolate mofetil (MMF) and she stopped taking salazosulfapyridine. The third day after that treatment, she had a high fever, fatigue, and joint pains of the knees, elbows, and wrists. RESULTS When the patient stopped taking TAC and MMF and started taking salazosulfapyridine again, she soon recovered. Next, we challenged same induction immunosuppression therapy with administration of salazosulfapyridine; however, the patient had the same symptom. We considered that the symptom was caused by TAC or MMF, and we did not challenge-test each drug. We found that taking only TAC caused the same symptom for the patient. Also, we challenged cyclosporine (CsA) with MMF and confirmed that she did not have the symptom. CONCLUSIONS We decided that drugs of the induction immunosuppression therapy were CsA, MMF, prednisolone, and basiliximab. The patient received induction therapy with plasmapheresis and rituximab in addition to the above-mentioned drugs, and we performed ABO-incompatible kidney transplantation for her. The post-surgical course was good, without acute rejection, and she had no pain.

Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients

Although the presence of tertiary Gleason pattern 5 is reportedly related to unfavorable prostate cancer characteristics, few data are available regarding the effects of tertiary Gleason pattern 5 on the new ISUP (International Society of Urological Pathology) grading system in radical prostatectomy patients. In this study, we evaluated the effect of tertiary Gleason pattern 5 on biochemical recurrence following radical prostatectomy in patients with prostate cancer. We retrospectively evaluated 1000 patients with prostate cancer who underwent radical prostatectomy. The ISUP Grades were as follows: Grade 1, 16.3%; Grade 2, 48.1% (with tertiary Gleason pattern 5, 8.0% and without tertiary Gleason pattern 5, 40.1%); Grade 3, 21.9% (with tertiary Gleason pattern 5, 9.1% and without tertiary Gleason pattern 5, 12.8%); Grade 4, 3.9%; and Grade 5, 9.8%. Biochemical recurrence-free survival differed significantly among the five groups (Grade 1–5) (P < 0.0001). Grade 2 with tertiary Gleason pattern 5 had a significantly worse prognosis than Grade 2 without tertiary Gleason pattern 5. Similarly, Grade 3 with tertiary Gleason pattern 5 demonstrated a significantly worse prognosis than Grade 3 without tertiary Gleason pattern 5. When Grade 2 and Grade 3 were divided with or without tertiary Gleason pattern 5, the survival curves differed significantly among Grade 1, Grade 2 without tertiary Gleason pattern 5, Grade 2 with tertiary Gleason pattern 5, Grade 3 without tertiary Gleason pattern 5, Grade 3 with tertiary Gleason pattern 5, and Grade 4 (P < 0.0001) (hazard ratios: 1, 1.14, 1.86, 2.23, 3.53, and 6.30). In a multivariate analysis, integrating tertiary Gleason pattern 5 into the ISUP Grade, PSA, and surgical margin status significantly predicted biochemical recurrence (P < 0.0001). Integrating tertiary Gleason pattern 5 into the ISUP grading system will improve the accuracy of patient outcome prediction following radical prostatectomy in patients with prostate cancer.

MP09-02 EFFECTS OF TADALAFIL ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH MALE LOWER URINARY TRACT SYMPTOMS INCLUDING BENIGN PROSTATIC ENLARGEMENT, BASED ON A URODYNAMIC STUDY

RESULTS: When considering extraprostatic extension (EPE), there was low concordance comparing the initial versus repeat MRI interpretation (K1⁄40.22). Additionally, when the senior radiologist re-read his own initial interpretation (n1⁄493, blinded to initial result), concordance for EPE was greater (K1⁄40.36) albeit similarly low. Regarding EPE, a comparison of initial MRI interpretation versus re-read by senior radiologist noted universal improvements in diagnostic characteristics include sensitivity (30.3% vs 56.1%), specificity (80.2% vs 88.6%), PPV (37.7% vs 66.1%), NPV (74.4% vs 83.6%), and accuracy (66.1% vs 79.4%). In contrast, seminal vesicle (SV) invasion interpretation was more uniform whereby initial MRI interpretation vs. re-read yielded similar sensitivity (18.2% vs 27.3%), specificity (97.2% vs 93.8%), PPV (40.0% vs 31.6%), NPV (91.9% vs 92.5%), and accuracy (89.7% vs 87.6%) (Table). CONCLUSIONS: Even at an academic medical center, interobserver agreement amongst radiologists to evaluate local extent of disease on prostate MRI is relatively low. We report, however, improved characteristics when a senior member of the body radiology team reads the MRI. These findings underscore the importance of uniformity when defining criteria for EPE and SV invasion to allow for appropriate surgical planning.

Identification of the narrow lumen of the ureter using a Fogarty catheter during laparoscopic pyeloplasty

It is difficult to identify the narrow sites of the ureter from the outside while carrying out laparoscopic pyeloplasty in patients with ureteropelvic junction obstruction. We developed and named a new method, the Fogarty test, to identify the narrow sites of the ureter using a Fogarty catheter. A 4‐ to 5‐Fr Fogarty catheter was inserted through an incision in the pelvis to the proximal ureter, inflated with air and withdrawn gently to determine resistance. The narrow lumen of the ureter was identified under direct vision and spatulated by laparoscopic scissors. This procedure was carried out repeatedly until the ureter was fully spatulated. By using the Fogarty test, we can visualize the narrow position and length of the ureter under direct vision, and confirm whether it is fully spatulated or not. This technique is very simple and easy to carry out. We believe it is useful for sufficient spatulation of intrinsic ureteral stricture, especially in patients where multiple narrow sites exist.